{
  "id": "6415c53e690f196b51000012",
  "type": "factoid",
  "question": "When was Keytruda approved by the FDA for the treatment of metastatic non-small cell lung cancer?",
  "ideal_answer": "On October 24, 2016, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda) for treatment of metastatic non-small cell lung cancer.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/28835513"
  ],
  "snippets": [
    {
      "text": "On October 24, 2016, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda; Merck & Co., Inc., https://www.merck.com) for treatment of patients with metastatic non-small cell lung cancer (mNSCLC) whose tumors express programmed death-ligand 1 (PD-L1) as determined by an FDA-approved test, as follows: (a) first-line treatment of patients with mNSCLC whose tumors have high PD-L1 expression (tumor proportion score [TPS] \u226550%), with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor aberrations, and (b) treatment of patients with mNSCLC whose tumors express PD-L1 (TPS \u22651%), with disease progression on or after platinum-containing chemotherapy. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28835513",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "October 24, 2016"
}